Pharmaceutical & Biotech
News and Insights
Pfizer and Allergan to merge
Pfizer and Allergan have agreed to a $160 billion dollar merger that will create the world's biggest pharmaceutical company. Pfizer's Ian Read will serve as CEO and Allergan's Brent Saunders will serve as president and chief operating officer. The deal will be completed as a reverse merger with Allergan buying Pfizer. This will ensure that Pfizer's tax rate will drop from 25% to around 17-18%. Click here to learn more about this merger. ...
Regeneron continues to grow
Regeneron announced on Thursday that it plans to expand its New York campus and add about 300 jobs. This is in addition to a 1,200 employee expansion this year with 945 of those new positions located in New York. Click here to view the entire article. ...
Here are some of the newly announced additions to company's throughout the industry. Insys has appointed the company's chairman and founder, John Kapoor, its new CEO. Juno Therapeutics appointed former vice president and general manager of Amgen Oncology, Robert Azelby, its new Chief Commercial Officer. Jounce Therapeutics appointed former chief medical officer at Promedior, Dr. Elizabeth Trehu, its Chief Medical Officer. Click here to learn more about with these executives have to offer in their new roles. ...
Eli Lilly shuts down global clinical study
Shares of Eli Lilly dropped 10% on the news that the company is shutting down its global Phase III study. The trial's lead drug, evacetrapib, is meant to avert heart attacks and strokes by blocking the protein CETP. The clinical trial had enrolled over 12,000 patients in 37 countries. Click here to read the entire article. ...
Merck's Keytruda gets FDA approval
Merck received an accelerated approval for its drug used to fight advanced non-small cell lung cancer. Keytruda's approval is for patients whose cancer has progressed after other treatments and who have tumors that express a protein called PD-L1. Lung cancer is the most common form of the disease and second in the United States advanced non-small cell lung cancer. Click here to view the entire article ...
Ely Lilly has to wait until December 2016 to release its Lantus biosimilar
Sanofi had been trying to hold off the release of biosimilars of its best-selling product, Lantus. In a recent ruling, Eli Lilly will have to wait until December 2016 to release its biosimilar form of Lantus SoloStar, the injectable pen. This is important for Sanofi because this form of the drug accounted for 62% of Lantus sales in the U.S. last year. Click here to learn more about the patent settlement agreement. ...
Turing Pharmaceuticals defends 5,000% price increase
Turing Pharmaceuticals acquired the rights to Daraprim, a drug used to treat AIDS patients, in August. Then last week raised the price from $13.50 a pill to $750 a pill. This 5000% increase will raise the annual treatment cost for a person weighing over 60 kg to $634,500. CEO Martin Shkreli said the price is still underpriced relative to its peers. The pricing increase has caused a storm of activity on social media as well as a call from elected officials to introduce drug-pricing legislation. Click here to view the entire article. ...
Tracking systems for pharmaceutical companies
Pharmaceutical companies are in the process of creating better tracking systems to monitor patient's use of their prescribed medications. This will not only help to prevent missed refills that are bad for a person's health but help their bottom line. Some of the options currently being talked about are to monitor patient's social media to track their reaction to medications, attaching tech tags to prescription bottles that send information back a data center or creating apps that will allow for increased communication with patients. Click here to view the entire article. ...
AstraZeneca names a new Head of R&D
Sean Bohen has been named head of AstraZeneca's R&D organization. He comes to AstraZeneca from Genentech where he has served as Senior Vice President of Early Development for 12 years. Mr. Bohen's appointment comes just two months after Briggs Morrison left AstraZeneca to become CEO of Syndax Pharmaceuticals. He is set to start on September 15th. Click here to view the entire article. ...
New website for children with life-threatening allergies
Disney and Mylan, a global generic and specialty pharmaceutical company, have teamed up to create a new website geared toward helping families that have children with serious allergies. The website, MyAllergyKingdom.com will be updated monthly with new information and tips for newly diagnosed patients. Click here to visit the website ...
1 of 3